Authors’ Disclosures
Durecki, P.
ONCOLOGY, EMD
M. Cecchini reports grants from NIH during the conduct of the study; personal fees from DAVA Oncology, BAYER, Seattle Genetics, Macrogenics, Taiho, Daiichi Sankyo, AstraZeneca; and other from Parthenon Therapeutics outside the submitted work. S.A. Boerner reports grants from NCI-CTEP during the conduct of the study. D.E. Durecki reports grants from NIH/NCI UM1CA186689 during the conduct of the study. K.A. Schalper reports personal fees from Clinica Alemana Santiago, Shattuck Labs, AstraZeneca, Takeda, Agenus, Genmab, Parthenon Therapeutics, Bristol-Myers Squibb, Sensei, Roche, Molecular Templates, Janssen, CDR life, Merck, PeerView, PER and Forefront collaborative; grants from Tesaro/GSK, Takeda, Surface Oncology, Merck, Bristol-Myers Squibb, AstraZeneca, Ribon Therapeutics, Eli Lilly, Boehringer-Ingelheim, Roche, Akoya Biosciences outside the submitted work. P. LoRusso reports personal fees from AbbVie, Agios, Five Prime, GenMab, Halozyme, Genentech, CytomX, Takeda, SOTIO, Cybrexa, Agenus, Tyme, IQVIA, TRIGR, Pfizer, ImmunoMet, Black Diamond, Glaxo-Smith Kline, QED Therapeutics, AstraZeneca, EMD Serono, Shattuck, Astellas, Salarius, Silverback, Macrogenics, Kyowa Kirin, Kineta, Zentalis, Molecular Templates, ABL Bio, SK Life, STCube, Bayer, I-Mab, Seagen, imCheck, Relay Therapeutics, Stemline, Compass BADX, Mekanist, Mersana, BAKX Therapeutics, Scenic Biotech, Qualigen, Roivant, NeuroTrials, and Actuate Therapeutics; other from Roche-Genentech outside the submitted work. No disclosures were reported by the other authors.